Financhill
Sell
11

BPTH Quote, Financials, Valuation and Earnings

Last price:
$0.16
Seasonality move :
5.23%
Day range:
$0.16 - $0.17
52-week range:
$0.12 - $3.39
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
9.98x
Volume:
32.4K
Avg. volume:
44.7K
1-year change:
-91.81%
Market cap:
$1.3M
Revenue:
--
EPS (TTM):
-$2.74

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
BPTH
Bio-Path Holdings
-- -$0.40 -- -92.21% $2.00
IMNN
Imunon
-- -$0.33 -- -34.8% $10.25
MTVA
MetaVia
-- -$0.65 -- -69.19% $14.33
NIKA
Nika Pharmaceuticals
-- -- -- -- --
TIVC
Tivic Health Systems
-- -- -- -- --
VYCO
Vycor Medical
-- -- -- -- --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
BPTH
Bio-Path Holdings
$0.16 $2.00 $1.3M -- $0.00 0% --
IMNN
Imunon
$0.60 $10.25 $8.8M -- $0.00 0% 15.97x
MTVA
MetaVia
$0.67 $14.33 $13.2M -- $0.00 0% --
NIKA
Nika Pharmaceuticals
$0.69 -- $708.2M 34,500.00x $0.00 0% --
TIVC
Tivic Health Systems
$3.95 -- $3.8M -- $0.00 0% 3.35x
VYCO
Vycor Medical
$0.13 -- $4.3M -- $0.00 0% 2.53x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
BPTH
Bio-Path Holdings
-- 0.396 -- --
IMNN
Imunon
-- 3.865 -- --
MTVA
MetaVia
-- 0.721 -- --
NIKA
Nika Pharmaceuticals
-- -0.473 -- 0.33x
TIVC
Tivic Health Systems
-- -1.682 -- 0.92x
VYCO
Vycor Medical
-31.82% 0.833 170.98% 0.06x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
BPTH
Bio-Path Holdings
-- -$3.2M -- -- -- -$1.3M
IMNN
Imunon
-- -$4.1M -- -- -- -$3.1M
MTVA
MetaVia
-- -$3.9M -- -- -- -$4.8M
NIKA
Nika Pharmaceuticals
-- -$13K -- -- -35128.21% -$12.9K
TIVC
Tivic Health Systems
$50K -$1.5M -192.41% -192.41% -2151.43% -$1.4M
VYCO
Vycor Medical
$358.5K -$12.8K -- -- -2.93% -$26.9K

Bio-Path Holdings vs. Competitors

  • Which has Higher Returns BPTH or IMNN?

    Imunon has a net margin of -- compared to Bio-Path Holdings's net margin of --. Bio-Path Holdings's return on equity of -- beat Imunon's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BPTH
    Bio-Path Holdings
    -- -$0.40 --
    IMNN
    Imunon
    -- -$0.28 --
  • What do Analysts Say About BPTH or IMNN?

    Bio-Path Holdings has a consensus price target of $2.00, signalling upside risk potential of 1165.82%. On the other hand Imunon has an analysts' consensus of $10.25 which suggests that it could grow by 1598.99%. Given that Imunon has higher upside potential than Bio-Path Holdings, analysts believe Imunon is more attractive than Bio-Path Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    BPTH
    Bio-Path Holdings
    0 0 0
    IMNN
    Imunon
    2 1 0
  • Is BPTH or IMNN More Risky?

    Bio-Path Holdings has a beta of -0.032, which suggesting that the stock is 103.201% less volatile than S&P 500. In comparison Imunon has a beta of 1.927, suggesting its more volatile than the S&P 500 by 92.726%.

  • Which is a Better Dividend Stock BPTH or IMNN?

    Bio-Path Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Imunon offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bio-Path Holdings pays -- of its earnings as a dividend. Imunon pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BPTH or IMNN?

    Bio-Path Holdings quarterly revenues are --, which are smaller than Imunon quarterly revenues of --. Bio-Path Holdings's net income of -$2.9M is higher than Imunon's net income of -$4.1M. Notably, Bio-Path Holdings's price-to-earnings ratio is -- while Imunon's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Path Holdings is -- versus 15.97x for Imunon. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BPTH
    Bio-Path Holdings
    -- -- -- -$2.9M
    IMNN
    Imunon
    15.97x -- -- -$4.1M
  • Which has Higher Returns BPTH or MTVA?

    MetaVia has a net margin of -- compared to Bio-Path Holdings's net margin of --. Bio-Path Holdings's return on equity of -- beat MetaVia's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BPTH
    Bio-Path Holdings
    -- -$0.40 --
    MTVA
    MetaVia
    -- -$0.36 --
  • What do Analysts Say About BPTH or MTVA?

    Bio-Path Holdings has a consensus price target of $2.00, signalling upside risk potential of 1165.82%. On the other hand MetaVia has an analysts' consensus of $14.33 which suggests that it could grow by 2027.55%. Given that MetaVia has higher upside potential than Bio-Path Holdings, analysts believe MetaVia is more attractive than Bio-Path Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    BPTH
    Bio-Path Holdings
    0 0 0
    MTVA
    MetaVia
    1 0 0
  • Is BPTH or MTVA More Risky?

    Bio-Path Holdings has a beta of -0.032, which suggesting that the stock is 103.201% less volatile than S&P 500. In comparison MetaVia has a beta of 0.214, suggesting its less volatile than the S&P 500 by 78.621%.

  • Which is a Better Dividend Stock BPTH or MTVA?

    Bio-Path Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MetaVia offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bio-Path Holdings pays -- of its earnings as a dividend. MetaVia pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BPTH or MTVA?

    Bio-Path Holdings quarterly revenues are --, which are smaller than MetaVia quarterly revenues of --. Bio-Path Holdings's net income of -$2.9M is higher than MetaVia's net income of -$3.7M. Notably, Bio-Path Holdings's price-to-earnings ratio is -- while MetaVia's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Path Holdings is -- versus -- for MetaVia. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BPTH
    Bio-Path Holdings
    -- -- -- -$2.9M
    MTVA
    MetaVia
    -- -- -- -$3.7M
  • Which has Higher Returns BPTH or NIKA?

    Nika Pharmaceuticals has a net margin of -- compared to Bio-Path Holdings's net margin of -35128.21%. Bio-Path Holdings's return on equity of -- beat Nika Pharmaceuticals's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BPTH
    Bio-Path Holdings
    -- -$0.40 --
    NIKA
    Nika Pharmaceuticals
    -- -- -$246.6K
  • What do Analysts Say About BPTH or NIKA?

    Bio-Path Holdings has a consensus price target of $2.00, signalling upside risk potential of 1165.82%. On the other hand Nika Pharmaceuticals has an analysts' consensus of -- which suggests that it could fall by --. Given that Bio-Path Holdings has higher upside potential than Nika Pharmaceuticals, analysts believe Bio-Path Holdings is more attractive than Nika Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    BPTH
    Bio-Path Holdings
    0 0 0
    NIKA
    Nika Pharmaceuticals
    0 0 0
  • Is BPTH or NIKA More Risky?

    Bio-Path Holdings has a beta of -0.032, which suggesting that the stock is 103.201% less volatile than S&P 500. In comparison Nika Pharmaceuticals has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock BPTH or NIKA?

    Bio-Path Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nika Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bio-Path Holdings pays -- of its earnings as a dividend. Nika Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BPTH or NIKA?

    Bio-Path Holdings quarterly revenues are --, which are smaller than Nika Pharmaceuticals quarterly revenues of $160. Bio-Path Holdings's net income of -$2.9M is lower than Nika Pharmaceuticals's net income of -$13K. Notably, Bio-Path Holdings's price-to-earnings ratio is -- while Nika Pharmaceuticals's PE ratio is 34,500.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Path Holdings is -- versus -- for Nika Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BPTH
    Bio-Path Holdings
    -- -- -- -$2.9M
    NIKA
    Nika Pharmaceuticals
    -- 34,500.00x $160 -$13K
  • Which has Higher Returns BPTH or TIVC?

    Tivic Health Systems has a net margin of -- compared to Bio-Path Holdings's net margin of -2145.71%. Bio-Path Holdings's return on equity of -- beat Tivic Health Systems's return on equity of -192.41%.

    Company Gross Margin Earnings Per Share Invested Capital
    BPTH
    Bio-Path Holdings
    -- -$0.40 --
    TIVC
    Tivic Health Systems
    71.43% -$2.52 $3M
  • What do Analysts Say About BPTH or TIVC?

    Bio-Path Holdings has a consensus price target of $2.00, signalling upside risk potential of 1165.82%. On the other hand Tivic Health Systems has an analysts' consensus of -- which suggests that it could fall by --. Given that Bio-Path Holdings has higher upside potential than Tivic Health Systems, analysts believe Bio-Path Holdings is more attractive than Tivic Health Systems.

    Company Buy Ratings Hold Ratings Sell Ratings
    BPTH
    Bio-Path Holdings
    0 0 0
    TIVC
    Tivic Health Systems
    0 0 0
  • Is BPTH or TIVC More Risky?

    Bio-Path Holdings has a beta of -0.032, which suggesting that the stock is 103.201% less volatile than S&P 500. In comparison Tivic Health Systems has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock BPTH or TIVC?

    Bio-Path Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tivic Health Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bio-Path Holdings pays -- of its earnings as a dividend. Tivic Health Systems pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BPTH or TIVC?

    Bio-Path Holdings quarterly revenues are --, which are smaller than Tivic Health Systems quarterly revenues of $70K. Bio-Path Holdings's net income of -$2.9M is lower than Tivic Health Systems's net income of -$1.5M. Notably, Bio-Path Holdings's price-to-earnings ratio is -- while Tivic Health Systems's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Path Holdings is -- versus 3.35x for Tivic Health Systems. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BPTH
    Bio-Path Holdings
    -- -- -- -$2.9M
    TIVC
    Tivic Health Systems
    3.35x -- $70K -$1.5M
  • Which has Higher Returns BPTH or VYCO?

    Vycor Medical has a net margin of -- compared to Bio-Path Holdings's net margin of -8.84%. Bio-Path Holdings's return on equity of -- beat Vycor Medical's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BPTH
    Bio-Path Holdings
    -- -$0.40 --
    VYCO
    Vycor Medical
    82.16% -$0.01 -$3M
  • What do Analysts Say About BPTH or VYCO?

    Bio-Path Holdings has a consensus price target of $2.00, signalling upside risk potential of 1165.82%. On the other hand Vycor Medical has an analysts' consensus of -- which suggests that it could fall by --. Given that Bio-Path Holdings has higher upside potential than Vycor Medical, analysts believe Bio-Path Holdings is more attractive than Vycor Medical.

    Company Buy Ratings Hold Ratings Sell Ratings
    BPTH
    Bio-Path Holdings
    0 0 0
    VYCO
    Vycor Medical
    0 0 0
  • Is BPTH or VYCO More Risky?

    Bio-Path Holdings has a beta of -0.032, which suggesting that the stock is 103.201% less volatile than S&P 500. In comparison Vycor Medical has a beta of -0.416, suggesting its less volatile than the S&P 500 by 141.563%.

  • Which is a Better Dividend Stock BPTH or VYCO?

    Bio-Path Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vycor Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bio-Path Holdings pays -- of its earnings as a dividend. Vycor Medical pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BPTH or VYCO?

    Bio-Path Holdings quarterly revenues are --, which are smaller than Vycor Medical quarterly revenues of $436.4K. Bio-Path Holdings's net income of -$2.9M is lower than Vycor Medical's net income of -$38.6K. Notably, Bio-Path Holdings's price-to-earnings ratio is -- while Vycor Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Path Holdings is -- versus 2.53x for Vycor Medical. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BPTH
    Bio-Path Holdings
    -- -- -- -$2.9M
    VYCO
    Vycor Medical
    2.53x -- $436.4K -$38.6K

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will GoodRX Stock Bounce Back?
Will GoodRX Stock Bounce Back?

GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…

Will FCX Benefit From Tariffs?
Will FCX Benefit From Tariffs?

Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…

Can Levi Stock Double?
Can Levi Stock Double?

Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…

Stock Ideas

Buy
71
Is NVDA Stock a Buy?

Market Cap: $4.2T
P/E Ratio: 58x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 43x

Sell
40
Is AAPL Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 35x

Alerts

Buy
72
SBET alert for Jul 18

SharpLink Gaming [SBET] is down 2.6% over the past day.

Buy
68
MCRI alert for Jul 18

Monarch Casino & Resort [MCRI] is up 19.81% over the past day.

Sell
41
NEGG alert for Jul 18

Newegg Commerce [NEGG] is up 17.85% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock